Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Shares Issued Shares Outstanding Shares Outstanding

Forte Biosciences (FBRX) Long-Term Debt Issuances (2016 - 2017)

Forte Biosciences (FBRX) has disclosed Long-Term Debt Issuances for 2 consecutive years, with $7.3 million as the latest value for Q1 2017.

Quarterly Long-Term Debt Issuances changed N/A to $7.3 million in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2017, changed N/A year-over-year, with the annual reading at $7.3 million for FY2017, 117.49% up from the prior year.
Long-Term Debt Issuances for Q1 2017 was $7.3 million at Forte Biosciences, up from $2.8 million in the prior quarter.
The five-year high for Long-Term Debt Issuances was $7.3 million in Q1 2017, with the low at $2.8 million in Q4 2016.